Twist Bioscience CEO Emily Leproust updated guidance at Baird's 2026 Global Healthcare Conference, forecasting Q4 FY2026 revenue of about $124 million, up 25% year over year for a 15th consecutive quarter, and a long-term goal of doubling revenue by 2031. She cited AI-driven drug discovery as a key driver, with related orders projected to rise from $25 million in 2025 to $50 million in 2026 and $100 million in 2027.